Bright eyes NAC eye drops for cataracts and lens treatment

Translate into German

...or Russian
...or Turkish

...or Slovenian

Site Name: biocare

The Ethos Group Schweiz

e-mail: info@ethos.ag
USA Toll Free
800-431-2698

Tel: +1-800-431-2698
Fax: +1-212-898-0462

UK FREE PHONE
0800 012 6946

Tel: +44 1462 44 11 33
Fax: +44 207 681 1018
Switzerland
24 hr Voice Mail/Fax
+41 44 274 28 27
Holland
24 hr Voice Mail/Fax
+31 205 241 583
Australia
24hr Voice Mail/Fax
+61 29 475 0171

Click Here

Click Here

Click Here

Click Here

Ethos élan vital

Ethos élan vital for Pets

People's Testimonials

Pet Testimonials

Ethos Stop 7

Marine Phytoplankton

Ethos Energy Eggs

Ethozyme

Cardio Track Machine

A B C D E F G H I J K L M N O

N-Acetyl-Carnosine (NAC) Bright Eyes Drops Naturally Dissolve Cataracts!

Ethos Endymion Bright Eyes Drops:

Maintaining eye health is a major concern as we age. As we get older our eyes have a harder time fighting off free radicals that cause oxidative stress. This highly oxidised environment within cells comes about as a result of a chemical reaction from exposure to oxygen and sunlight. Since the lens of the eye acts as a light shield for the retina, it’s no wonder it takes all the oxidative punishment. The destructive action of free radicals (they are oxidising agents) also destroys enzymes that are needed to maintain cellular metabolism. And, since blood flow decreases with age, the eye is further deprived of other essential nutrients for health.

Although many praise the benefits of dietary supplements, another way of preventing and treating eye disorders is through topical solutions.

Ethos Endymion Bright Eyes is one of the most advanced eye formulas that offer protection from free radicals because of its unique formulation of lubricants, an anti-glycating agent, and antioxidant. Glycation occurs as a result of nonenzymatic binding of sugar to protein, which eventually leads to tissue damage. It’s a condition that increases with age.

The newly formulated Endymion Bright Eyes contains 1% N-Acetyl-L-Carnosine, a naturally occurring antioxidant and anti-glycating agent that, when topically applied, can penetrate and protect the lipid tissues of the eye against light damage. Bright Eyes will help to diminish free radical damage and the harmful effects of glycosylation associated with degenerative eye disease.

Bright Eyes Ingredients:

	Antioxidants: N-Acetyl-Carnosine (NAC) - 1.0% Glycerin (lubricant) - 1.0% Hydroxypropylmethylcellulose Sodium (lubricant) - 0.15% Sterile Water (ophthalmic grade isotonic solution, pH 6.3 to 6.5) Buffered with Boric Acid, Citric Acid and Potassium Bicarbonate And, as a preservative, Purified Benzyl Alcohol

Other Information:

Bright Eyes is 100% hypoallergenic.
Bright Eyes is 100% free of animal ingredients and may be freely used by vegetarians.
Bright Eyes is 100% safe and suitable for use on pets and other animals.

Bright Eyes Recommended Usage:

The recommended use for Bright Eyes NAC eyes drops is to apply 1 to 2 drops in each eye daily. Those with any kind of eye problem may want to apply 1 to 2 drops several times a day.

Each 5ml bottle should last 30 days at two drops per day or 15 days at four drops per day. A box contains 2 x 5ml bottles; therefore each package can last between 30 and 60 days which represents excellent value for money.

Unopened bottles should be stored in the dark in the refrigerator.

The use of Carnosine as an anti-senescence supplement

From our investigations, we have reported that eye drops containing 20 mM carnosine were used to treat 96 patients aged 60 years old having senile cataract of various degrees of maturity, with the duration of the disease from 2 to 21 years. The method is that after stopping all other anti-cataract drugs, patients instilled 1-2 drops of the carnosine containing solution in each eye 3-4 times each day for a period of treatment ranging from 3-6 months. The level of eyesight improvement and the change of lens transparency were considered as an evaluation index of the curative effect of carnosine.

The result shows that carnosine gives a profound effect on primary senile cataract, the effective rate being 100%.

For mature senile cataract, the effect rate is 80%, and positive effects were observed with other types of cataract.

It is significant that no side effect has been found in the observed cases. During recent years, we have also applied carnosine drops containing the same content to nearly 1,000 patients with senile cataract. Our research findings (ready to be published) show similar results.

In addition, we applied carnosine drops to patients aged 48-60 years with various degrees of eyesight impairment but without symptoms of cataract. The course of treatment is from 2 to 6 months. The results demonstrate that carnosine appears to alleviate eye tiredness and comparatively improve eyesight (obviously improve eyesight, giving more clear vision). Subjects reported that carnosine could brighten and relax their eyes.

It is an important point that all the above research on the medical application of carnosine has statistical significance.

The efficacy of N-acetylcarnosine in the treatment of cataracts

Babizhayev MA, Deyev AI, Yermakova VN, Semiletov YA, Davydova NG, Doroshenko VS, Zhukotskii AV, Goldman IM.

PURPOSE: To evaluate the effects of 1% N-acetylcarnosine (NAC) solution on lens clarity over 6 and 24 months in patients with cataracts. TRIAL DESIGN: Randomised, placebo-controlled study.

PARTICIPANTS: 49 subjects (76 affected eyes) with an average age of 65.3 +/- 7.0 years with a diagnosis of senile cataract with minimum to advanced opacification in various lens layers. METHODS: 26 patients (41 eyes) were allocated to topical NAC 1% eyedrops twice daily.

The control group consisted of 13 patients (21 eyes) who received placebo eyedrops and 10 patients (14 eyes) who did not receive eyedrops.

MAIN OUTCOME MEASURES: All patients were evaluated at entry and followed up every 2 months for a 6-month period (trial 1), or at 6-month intervals for a 2-year period (trial 2), for best-corrected visual acuity and glare testing. In addition, cataract was measured using stereocinematographic slit-images and retro-illumination examination of the lens. Digital analysis of lens images displayed light scattering and absorbing centres in two- and three-dimensional scales.

RESULTS: The overall intra-reader reproducibility of cataract measurements (image analysis) was 0.830, and glare testing 0.998. After 6 months, 90% of NAC-treated eyes showed improvement in best corrected visual acuity (7 to 100%) and 88.9% showed a 27 to 100% improvement in glare sensitivity.

Topographic studies indicated fewer areas of posterior subcapsular lens opacity and 41.5% of treated eyes had improvement in image analysis characteristics. The overall ratios of image analysis characteristics at 6 months compared with baseline measures were 1.04 and 0.86 for the control and NAC-treated group, respectively (p < 0.001). The apparent benefits of treatment were sustained after 24 months' treatment.

No treated eyes demonstrated worsening of vision. The overall visual outcome in the control group showed significant worsening after 24 months in comparison with both baseline and the 6-month follow-up examination. The overall clinical results observed in the NAC-treated group by the 24-month period of examination differed significantly (p < 0.001) from the control group in the eyes with cortical, posterior subcapsular, nuclear or combined lens opacities. Tolerability of NAC eyedrops was good in almost all patients, with no reports of ocular or systemic adverse effects.

CONCLUSION: Topical NAC shows potential for the treatment and prevention of cataracts.

Publication Types:

Clinical Trial

Randomised Controlled Trial

The photographs below show images of a lens with senile cataract (corticonuclear opacities, grade 4, age 75 years, female), and the subsequent slit images in optical section documenting in the focal plane: (a) marked light scattering in the nucleus and posterior cortical region outlined by the lens optical scanning with the focal plane movement inside the lens thickness; (b) light scattering in the anterior subcapsular, anterior cortical and nuclear regions of the lens; retro-illumination lens images with a focal plane positioned (c) onto the iris and (d) on the posterior lens layers. Opacities in the cortical layers are demonstrated as the white background inclusions in the boundary of the pupil locally masked by the flashlight article. (e) the neutral density step reference wedge captured in the plane of the camera focus and allowing correction for variations in film development and flashlight output.

In the NAC-treated group, 6-month follow-up showed an improvement in VA (7-100%) in 37 of the 41 treated eyes and a significant improvement in glare sensitivity at red and green targets (27-100%) was documented in 16 of the 18 eyes tested. A significant improvement in lens clarity was found in 17 of the 41 eyes as documented by a significant decrease of M and H characteristics during image grading. The NAC-treated eyes had statistically significant differences in VA, glare sensitivity and characteristics of image analysis compared with the control group (p < 0.001) at this time point, as supported by the overall t-test results of the ratio of the follow-up data to the baseline values.